The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Independent evaluation of ibrutinib efficacy 3 years post-initiation of monotherapy in patients with chronic lymphocytic leukemia/small lymphocytic leukemia including deletion 17p disease.
Susan Mary O'Brien
Research Funding - Pharmacyclics
Richard R. Furman
Consultant or Advisory Role - Janssen; Pharmacyclics
Honoraria - Janssen
Steven E. Coutre
Consultant or Advisory Role - Pharmacyclics
Research Funding - Pharmacyclics
Ian Flinn
Research Funding - Janssen; Pharmacyclics
Jan Andreas Burger
Consultant or Advisory Role - Celgene; Gilead Sciences; Novartis; Pharmacyclics
Research Funding - Celgene; Pharmacyclics
Kristie A. Blum
No relevant relationships to disclose
Jeff Porter Sharman
Consultant or Advisory Role - Celgene
Honoraria - Genentech; Gilead Sciences; Pharmacyclics
Research Funding - Celgene; Genentech; Gilead Sciences; Pharmacyclics
Other Remuneration - Gilead Sciences
Jeffrey Alan Jones
Consultant or Advisory Role - Janssen; Pharmacyclics
Research Funding - Pharmacyclics
William G. Wierda
Consultant or Advisory Role - Pharmacyclics
Research Funding - Pharmacyclics
Weiqiang Zhao
No relevant relationships to disclose
Nyla A. Heerema
No relevant relationships to disclose
Amy J. Johnson
No relevant relationships to disclose
Anh Tran
Employment or Leadership Position - Pharmacyclics
Stock Ownership - Pharmacyclics
Cathy Zhou
Employment or Leadership Position - Pharmacyclics
Stock Ownership - Pharmacyclics
Elizabeth Bilotti
Employment or Leadership Position - Pharmacyclics
Stock Ownership - Pharmacyclics
Danelle Frances James
Employment or Leadership Position - Pharmacyclics
Stock Ownership - Pharmacyclics
John C. Byrd
Research Funding - Pharmacyclics